DAFTAR PUSTAKA

Admoun, C., & Mayrovitz, H. N. (2022). The Etiology of Breast Cancer. *Breast Cancer*. https://doi.org/10.1016/S0140-6736(01)20894-0

Azim, H. A., & Partridge, A. H. (2014). Biology of Breast Cancer in Young Women. *Breast Cancer Research*, *16*(4), 1–9. https://doi.org/10.1186/s13058-014-0427-5

Badowska-Kozakiewicz, A., Sobol, M., & Patera, J. (2016). Expression of hypoxia-inducible factor 1α in invasive breast cancer with metastasis to lymph nodes: Correlation with steroid receptors, HER2 and EPO-R. *Advances in Clinical and Experimental Medicine*, *25*(4), 741–750. https://doi.org/10.17219/acem/63143

Bhutta, B. S., Alghoula, F., & Berim, I. (2022). *Hypoxia*. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK482316/

Blackburn, H. L., Ellsworth, D. L., Shriver, C. D., & Ellsworth, R. E. (2017). Breast cancer metastasis to the axillary lymph nodes: Are changes to the lymph node “Soil” localized or systemic? *Breast Cancer: Basic and Clinical Research*, *11*. https://doi.org/10.1177/1178223417691246

Bos, R., Van Diest, P. J., De Jong, J. S., Van Der Groep, P., Van Der Valk, P., & Van Der Wall, E. (2005). Hypoxia-inducible factor-1α is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. *Histopathology*, *46*(1), 31–36. https://doi.org/10.1111/j.1365-2559.2005.02045.x

Bos, R., Zhong, H., Semenza, G. L., Herbert, M., Abeloff, M. D., Simons, W., & Diest, P. J. Van. (2001). *Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis*. *93*(4), 309–314. https://doi.org/10.1093/jnci/93.4.309

Britannica, T. (2023). *Hypoxia*. Encyclopedia Britannica. https://www.britannica.com/science/hypoxia

Cao, Q., Mushajiang, M., Tang, C. qiong, & Ai, X. qing. (2023). Role of hypoxia-inducible factor-1α and survivin in breast cancer recurrence

and prognosis. *Heliyon*, *9*(3), e14132. https://doi.org/10.1016/j.heliyon.2023.e14132

Centers for Disease Control and Prevention. (2022). *What is breast cancer?* Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm

Collin, L. C. (2018). Breast. In J. R. Goldblum (Ed.), *Rosai and Ackerman's Surgical Pathology* (11th ed., pp. 1434–1529). Elsevier.

Collin, L. J., Maliniak, M. L., Cronin-Fenton, D. P., Ahern, T. P., Christensen, K. B., Ulrichsen, S. P., Damkier, P., Hamilton-Dutoit, S., Yacoub, R., Christiansen, P. M., Sørensen, H. T., & Lash, T. L. (2021). Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study. *Breast Cancer Research*, *23*(1), 1–11. https://doi.org/10.1186/s13058-021-01480-1

Ebright, R. Y., Zachariah, M. A., Micalizzi, D. S., Wittner, B. S., Niederhoffer, K. L., Nieman, L. T., Chirn, B., Wiley, D. F., Wesley, B., Shaw, B., Nieblas-Bedolla, E., Atlas, L., Szabolcs, A., Iafrate, A. J., Toner, M., Ting, D. T., Brastianos, P. K., Haber, D. A., & Maheswaran, S. (2020). HIF1A signaling selectively supports proliferation of breast cancer in the brain. *Nature Communications*, *11*(1), 1–13. https://doi.org/10.1038/s41467-020-20144-w

Ellenson, L. H., & Lester, S. C. (2018). Female Genital System and Breast. In V. Kumar, A. K. Abbas, & J. C. Aster (Eds.), *Robbins Basic Pathology* (10th ed., pp. 736–747). Elsevier.

Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T. C., & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes and Diseases*, *5*(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001

Glikes, D. M., & Semenza, G. L. (2013). Role of hypoxia-inducible factors in breast cancer metastasis. *Future Oncology*, *9*(11), 1623–1636. https://doi.org/10.2217/fon.13.92

Harrison, H., Pegg, H. J., Thompson, J., Bates, C., & Shore, P. (2018). HIF1-alpha expressing cells induce a hypoxic-like response in neighbouring cancer cells. *BMC Cancer*, *18*(1), 1–9. https://doi.org/10.1186/s12885-018-4577-1

Hypoxia-inducible Factors - An Overview. (2019). ScienceDirect Topics. https://www.sciencedirect.com/topics/neuroscience/hypoxia-inducible-factors

Ke, Q., & Costa, M. (2006). Hypoxia-Inducible Factor-1 (HIF-1). *Molecular Pharmacology*, *70*(5), 1469–1480. https://doi.org/10.1124/mol.106.027029.

Kim, L. C., & Simon, M. C. (2022). Hypoxia-Inducible Factors in Cancer. Cancer research, 82(2), 195–196. https://doi.org/10.1158/0008-5472.CAN-21-3780

Kozal, K., & Krześlak, A. (2022). The Role of Hypoxia-Inducible Factor Isoforms in Breast Cancer and Perspectives on Their Inhibition in Therapy. *Cancers*, *14*(18), 4518. https://doi.org/10.3390/cancers14184518

Kronblad, A., Jirström, K., Rydén, L., Nordenskjöld, B., & Landberg, G. (2006). Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. International journal of cancer, 118(10), 2609–2616. https://doi.org/10.1002/ijc.21676

Kuhn, E., Gambini, D., Despini, L., Asnaghi, D., Runza, L., & Ferrero, S. (2023). Updates on Lymphovascular Invasion in Breast Cancer. *Biomedicines*, *11*(3), 968. https://doi.org/10.3390/biomedicines11030968

Liu, Z. ji, Semenza, G. L., & Zhang, H. feng. (2015). Hypoxia-inducible factor

1 and breast cancer metastasis. *Journal of Zhejiang University: Science B*, *16*(1), 32–43. https://doi.org/10.1631/jzus.B1400221

Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021). Breast Cancer. *The Lancet*, *397*, 1750–1769. https://doi.org/10.1016/S0140-6736(20)32381-3

Lukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanislawek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies— An Updated Review. *Cancers*, *13*, 4287. doi:10.3390/cancers13174287

Masoud, G. N., & Li, W. (2015). HIF-1α pathway: Role, regulation and intervention for cancer therapy. *Acta Pharmaceutica Sinica B*, *5*(5), 378–389. https://doi.org/10.1016/j.apsb.2015.05.007

Moon, E. J., Mello, S. S., Li, C. G., Chi, J. T., Thakkar, K., Kirkland, J. G., Lagory, E. L., Lee, I. J., Diep, A. N., Miao, Y., Rafat, M., Vilalta, M., Castellini, L., Krieg, A. J., Graves, E. E., Attardi, L. D., & Giaccia, A. J. (2021). The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. *Nature Communications*, *12*(1). https://doi.org/10.1038/s41467-021-24631-6

Nalwoga, H., Ahmed, L., Arnes, J. B., Wabinga, H., & Akslen, L. A. (2016). Strong expression of hypoxia-inducible factor-1α (HIF-1α) is associated with Axl expression and features of aggressive tumors in African breast cancer. *PLoS ONE*, *11*(1), 1–17. https://doi.org/10.1371/journal.pone.0146823

Nathanson, S. D. (2003). Insights into the mechanisms of lymph node metastasis. *Cancer*, *98*(2), 413–423. https://doi.org/10.1002/cncr.11464

Nathanson, S. D., Detmar, M., Padera, T. P., Yates, L. R., Welch, D. R., Beadnell, T. C., Scheid, A. D., Wrenn, E. D., & Cheung, K. (2022). Mechanisms of breast cancer metastasis. *Clinical and Experimental Metastasis*, *39*(1), 117–137. https://doi.org/10.1007/s10585-021-

10090-2

Ni, X., Zhao, Y., Ma, J., Xia, T., Liu, X., Ding, Q., Zha, X., & Wang, S. (2013). Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients. *Journal of Biomedical Research*, *27*(6), 478–485. https://doi.org/10.7555/JBR.27.20130021

Pezzuto, A., & Carico, E. (2018). Role of HIF-1 in Cancer Progression: Novel Insights. A Review. *Current Molecular Medicine*, *18*(6), 343–351. https://doi.org/10.2174/1566524018666181109121849

Rahman, M., & Mohammed, S. (2015). Breast cancer metastasis and the lymphatic system (Review). *Oncology Letters*, *10*(3), 1233–1239. https://doi.org/10.3892/ol.2015.3486

Rakha, E. A., & Ellis, I. O. (2010). Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Research*, *12*(207), 260–271. https://doi.org/10.1016/B978-1-4377-1757-0.00019-6

Rakha, E., Allison, K., Ellis, I., & Llorca, F. P. (2019). Invasive Breast Carcinoma: General Overview. In *WHO Classification of Tumours: Breast Tumours* (5th ed., pp. 82–101).

Rakha, E., Allison, K., Schnitt, S., & Llorca, F. P. (2019). Invasive Breast Carcinoma of No Special Type. In *WHO Classification of Tumours: Breast Tumours Breast Tumours* (5th ed., pp. 102–109).

Ran, S., Volk, L., Hall, K., & Flister, M. J. (2010). Lymphangiogenesis and lymphatic metastasis in breast cancer. *Pathophysiology*, *17*(4), 229–251. https://doi.org/10.1016/j.pathophys.2009.11.003

Schito, L., Rey, S., Tafani, M., Zhang, H., Wong, C. C. L., Russo, A., Russo, M. A., & Semenza, G. L. (2012). Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, *109*(40). https://doi.org/10.1073/pnas.1214019109

Schoppmann, S. F., Fenzl, A., Schindl, M., Bachleitner-Hofmann, T., Nagy, K., Gnant, M., Horvat, R., Jakesz, R., & Birner, P. (2006). Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer. *Breast Cancer Research and Treatment*, *99*(2), 135–141. https://doi.org/10.1007/s10549-006-9190-

Semenza, G. L. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. *Science's STKE : Signal Transduction Knowledge Environment*, *2007*(407), 9–12. https://doi.org/10.1126/stke.4072007cm8

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Takada, K., Kashiwagi, S., Asano, Y., Goto, W., Kouhashi, R., Yabumoto, A., Morisaki, T., Shibutani, M., Takashima, T., Fujita, H., Hirakawa, K., & Ohira, M. (2020). Prediction of lymph node metastasis tumor-infiltrating lymphocytes in T1 breast cancer. *BMC Cancer*, *20*(598). https://doi.org/10.21873/anticanres.14202

Toss, A., Venturelli, M., Peterle, C., Piacentini, F., Cascinu, S., & Cortesi, L. (2017). Molecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: Trick or treat? *International Journal of Molecular Sciences*, *18*(1), 85. https://doi.org/10.3390/ijms18010085

Weidemann, A., & Johnson, R. S. (2008). Biology of HIF-1α. *Cell Death and Differentiation*, *15*, 621–627. https://doi.org/10.1038/cdd.2008.12

Xia, X., & Kung, A. L. (2009). Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. *Genome Biology*, *10*(10), R113. https://doi.org/10.1186/gb-2009-10 10-r113

Zhang, Q., Han, Z., Zhu, Y., Chen, J., & Li, W. (2021). Role of hypoxia inducible factor-1 in cancer stem cells (Review). *Molecular Medicine Reports*, *23*(1). https://doi.org/10.3892/mmr.2020.11655

Zhang, Z., Yao, L., Yang, J., Wang, Z., & Du, G. (2018). PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia (Review). *Molecular Medicine Reports*, *18*(4), 3547–3554. https://doi.org/10.3892/mmr.2018.9375

Ziello, J. E., Jovin, I. S., & Huang, Y. (2007). Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. *Yale Journal of Biology and Medicine*, *80*(2), 51–60.

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 553/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 9 Agustus 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23070473	No Sponsor	
Peneliti Utama	**dr. Agnes Dyah Christinahadi**	Sponsor	
Judul Peneliti	Hubungan Ekspresi Hypoxia Inducible Factor-1 Alpha (Hif-1a) Dengan Derajat Histopatologi, Invasi Limfovaskular & Metastasis Ke Kelenjar Getah Bening Pada Karsinoma Payudara Invasif		
No Versi Protokol	**1**	Tanggal Versi	**4 Juli 2023**
No Versi PSP	**1**	Tanggal Versi	**4 Juli 2023**
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **9 Agustus 2023** sampai **9 Agustus 2024**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

USIA	USIA_KAT	INTENSITAS	PROPORSI	IRS	IRS_KAT	DH	DH_KAT	LVSI	LVSI_KAT	METASTASIS_KAT
34 thn	1	1	2	2	2	G1 M	1	Positif	2	1
48 thn	1	3	1	3	1	G1 M	1	Positif	2	1
38 thn	1	1	1	1	2	G1 M	1	Positif	2	1
47 thn	1	3	3	9	1	G1 M	1	Positif	2	1
51 thn	2	3	3	9	1	G1 M	1	Negatif	1	1
35 thn	1	1	2	2	2	G1 M	1	Positif	2	1
56 thn	2	1	2	2	2	G1 M	1	Negatif	1	1
44 thn	1	1	1	1	2	G1 M	1	Positif	2	1
45 thn	1	2	2	4	1	G1 M	1	Negatif	1	1
46 thn	1	2	2	4	1	G1 M	1	Positif	2	1
61 thn	2	1	1	1	2	G1 M	1	Positif	2	1
58 thn	2	1	3	3	1	G1 M	1	Positif	2	1
49 thn	1	1	1	1	2	G1 M	1	Positif	2	1
49 thn	1	1	1	1	2	G1 M	1	Positif	2	1
66 thn	2	2	3	6	1	G1 M	1	Negatif	1	1
52 thn	2	3	3	9	1	G1 M	1	Positif	2	1
54 thn	2	1	2	2	2	G1 M	1	Positif	2	1
44 thn	1	2	3	6	1	G1 M	1	Positif	2	1
49 thn	1	1	2	2	2	G1 M	1	Positif	2	1
56 thn	2	3	2	6	1	G1 NM	1	Negatif	1	2
39 thn	1	1	2	2	2	G1 NM	1	Negatif	1	2
43 thn	1	1	1	1	2	G1 NM	1	Negatif	1	2
47 thn	1	1	1	1	2	G1 NM	1	Negatif	1	2
33 thn	1	1	2	2	2	G1 NM	1	Negatif	1	2
55 thn	2	3	3	9	1	G2 M	2	Positif	2	1
49 thn	1	1	1	1	2	G2 M	2	Positif	2	1
64 thn	2	2	1	2	2	G2 M	2	Negatif	1	1
44 thn	1	3	2	6	1	G2 M	2	Positif	2	1
83 thn	2	2	2	4	1	G2 M	2	Positif	2	1

Variabel koding	Koding
Usia	1 <50 tahun
	2 >=50 tahun
IRS	1= positif
	2= negatif
Derajat histopatologi	1= derajat 1
	2= derajat 2
	3= derajat 3
Metastasis	1= metastasis
	2= non-metastasis
LVSI	1= positif
	2= negatif

56 thn	2	3	3	9	1	G2 M	2	Positif	2	1
51 thn	2	3	3	9	1	G2 M	2	Positif	2	1
55 thn	2	2	1	2	2	G2 M	2	Positif	1	1
51 thn	2	1	1	1	2	G2 M	2	Negatif	1	1
48 thn	1	3	2	6	1	G2 M	2	Negatif	1	1
64 thn	2	3	3	9	1	G2 M	2	Positif	2	1
55 thn	2	1	3	3	1	G2 M	2	Positif	2	1
46 thn	1	2	3	6	1	G2 M	2	Positif	2	1
38 thn	1	1	2	2	2	G2 M	2	Positif	2	1
56 thn	2	3	2	6	1	G2 M	2	Negatif	1	1
32 thn	1	1	1	1	2	G2 M	2	Negatif	1	1
53 thn	2	3	3	9	1	G2 M	2	Positif	2	1
40 thn	1	3	3	9	1	G2 M	2	Negatif	1	1
56 thn	2	1	2	2	2	G2 NM	2	Negatif	1	2
43 thn	1	1	1	1	2	G2 NM	2	Negatif	1	2
50 thn	2	1	1	2	2	G2 NM	2	Negatif	1	2
56 thn	2	2	2	4	1	G2 NM	2	Negatif	1	2
59 thn	2	2	2	4	1	G2 NM	2	Positif	2	2
58 thn	2	3	3	9	1	G2 NM	2	Negatif	1	2
43 thn	1	1	1	1	2	G2 NM	2	Negatif	1	2
33 thn	1	1	2	2	2	G2 NM	2	Negatif	1	2
70 thn	2	3	3	9	1	G3 M	3	Positif	2	1
42 thn	1	2	2	4	1	G3 M	3	Positif	2	1
39 thn	1	1	2	2	2	G3 M	3	Negatif	1	1
62 thn	2	3	3	9	1	G3 M	3	Positif	2	1
63 thn	2	1	1	1	2	G3 M	3	Positif	2	1
68 thn	2	1	3	3	1	G3 M	3	Positif	2	1
78 thn	2	1	2	2	2	G3 M	3	Positif	2	1
60 thn	2	3	3	9	1	G3 M	3	Positif	2	1
70 thn	2	1	3	3	1	G3 M	3	Positif	2	1

66 thn	2	3	3	9	1	G3 M	3	Positif	2	1
43 thn	1	3	2	6	1	G3 M	3	Positif	2	1
62 thn	2	2	2	4	1	G3 M	3	Positif	2	1
40 thn	1	2	2	4	1	G3 M	3	Positif	2	1
65 thn	2	3	3	9	1	G3 M	3	Positif	2	1
67 thn	2	3	2	6	1	G3 M	3	Positif	2	1
56 thn	2	3	3	9	1	G3 M	3	Positif	2	1
50 thn	2	3	3	9	1	G3 M	3	Positif	2	1
42 thn	1	3	2	6	1	G3 M	3	Positif	2	1
41 thn	1	2	2	4	1	G3 M	3	Positif	2	1
50 thn	2	3	2	6	1	G3 M	3	Positif	2	1
50 thn	2	3	3	9	1	G3 M	3	Positif	2	1
42 thn	1	1	3	3	1	G3 M	3	Positif	2	1
61 thn	2	2	2	4	1	G3 M	3	Positif	2	1
47 thn	1	3	2	6	1	G3 M	3	Positif	2	1
45 thn	1	1	3	3	1	G3 M	3	Positif	2	1
59 thn	2	3	1	3	1	G3 M	3	Positif	2	1
62 thn	2	2	3	6	1	G3 M	3	Positif	2	1
44 thn	1	3	1	3	1	G3 NM	3	Negatif	1	2
49 thn	1	2	1	2	2	G3 NM	3	Negatif	1	2
53 thn	2	3	3	9	1	G3 NM	3	Negatif	1	2